VAXCYTE INC. - COMMON STOCK

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

01 مايو 2025 08:00:29 بحسب Nasdaq GlobeNewswire

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

31 مارس 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

30 مارس 2025 17:00:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

25 فبراير 2025 16:01:00 بحسب Nasdaq GlobeNewswire

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

12 فبراير 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

05 فبراير 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

30 يناير 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

03 ديسمبر 2024 08:00:22 بحسب Nasdaq GlobeNewswire

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

12 نوفمبر 2024 07:30:11 بحسب Nasdaq GlobeNewswire

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

05 نوفمبر 2024 16:01:35 بحسب Nasdaq GlobeNewswire

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

11 سبتمبر 2024 16:05:03 بحسب Nasdaq GlobeNewswire

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

06 سبتمبر 2024 16:05:46 بحسب Nasdaq GlobeNewswire

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

04 سبتمبر 2024 23:58:41 بحسب Nasdaq GlobeNewswire

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

03 سبتمبر 2024 16:01:32 بحسب Nasdaq GlobeNewswire

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

03 سبتمبر 2024 07:07:43 بحسب Nasdaq GlobeNewswire

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

02 سبتمبر 2024 18:40:59 بحسب Nasdaq GlobeNewswire

Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update

06 أغسطس 2024 16:05:01 بحسب Nasdaq GlobeNewswire

Vaxcyte Appoints John Furey to Board of Directors

02 يوليو 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

08 مايو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference

02 أبريل 2024 16:05:51 بحسب Nasdaq GlobeNewswire